Key result
Olanzapine raises triglycerides, total cholesterol, and LDL-C while lowering HDL-C, particularly at higher doses.
Why the study?
Does olanzapine alter lipid profiles (TG, TC, HDL-C, LDL-C) in humans?
Does olanzapine alter lipid profiles (TG, TC, HDL-C, LDL-C) in humans?
Olanzapine treatment causes significant dose- and time-dependent worsening of lipid profiles (increased TG, TC, LDL-C), highlighting the need for proactive lipid monitoring and cardiovascular risk assessment.
Answers are grounded in this paper and cite their sources.
Requires lipid monitoring with olanzapine; confirms and extends RCT evidence of dose- and time-dependent dyslipidemia.
Olanzapine treatment is associated with a distinct dyslipidemic profile, characterized by increased TG, TC, and LDL-C and reduced HDL-C, particularly at higher doses and during early treatment. These findings underscore the need for proactive lipid monitoring and cardiovascular risk assessment, especially in patients with low baseline BMI, who appear more susceptible to rapid lipid alterations, and in those with existing metabolic risk factors or multiple cardiometabolic comorbidities.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question. Olanzapine treatment increased triglycerides, total cholesterol, and LDL-C while reducing HDL-C, particularly at higher doses and early treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: